Searched for
HETERO HEALTHCARE LTD
Regulator, cos discuss price hike for some cancer drugsIndia's drug pricing authority may soon approve a price hike for vital platinum-based cancer medicines. These drugs, including carboplatin ...
Hetero gets DCGI nod to manufacture, market Molnupiravir capsulesUnder the licensing deal, Hetero will be allowed to expand access of Molnupiravir in India and in other low-and middle-income countries, fo...
Hetero gets DGCI approval for generic version of tocilizumab for treatment of Covid-19"The Drug Controller General of India (DCGI) has issued for restricted use, Emergency Use Authorisation (EUA) for the generic version of To...
Hetero launches pack of generic COVID-19 drug favipiravir at Rs 2,640"The launch of 'Favivir 800/200' is aimed at enhancing patients' adherence to treatment regimen by reducing the number of pills they are re...
Hetero launches Favipiravir in India under the brand ‘Favivir’ to treat Covid-19This is the second drug developed by Hetero after Covifor, the generic version of Remdesivir injection to be administered intravenously in ...
Hetero starts supply of 60,000 vials of generic Remdesvir for treatment of Covid-19 patientsCovifor is the first generic brand of Remdesivir, which is meant for treatment of COVID-19 patients that are adults and children, hospitali...
Drug controller asks states to enforce maximum retail price for RemdesivirThe drug controller has said that the importer of the drug (Gilead pharma) took an import licence on 1st of June and is yet to supply the d...
Gilead won't launch its Covid drug in JulyGilead has issued licences to nine generic drug companies to make and sell remdesivir. Six of the companies are Indian - Hetero, Cipla, Dr ...
Hetero dispatches 10k vials of Remdesivir for Covid-19 treatmentThe Hyderabad-headquartered Hetero said it will dispatch second batch of 10,000 vials of the generic drug in the injectable form (100mg via...
Hetero Healthcare set to supply its generic COVID-19 drug at Rs 5,400 per vial across IndiaThe company is set to deliver the first set of 20,000 vials in two equal lots of 10,000 each, one of which will be immediately supplied to ...
Hetero gets DCGI nod to launch Remdesivir for Covid-19 treatmentHetero will produce and launch the first generic Remdesivir under Covifor brand in India following positive clinical outcomes under a licen...
Hetero launches generic breast cancer treatment drug in IndiaDrug firm Hetero Friday said it has launched generic Lapatinib tablets, used in the treatment of advanced or metastatic breast cancer in th...
Hetero launches HumiraTM biosimilar in IndiaThe product will be marketed by Hetero Healthcare under the brand name ‘MaburaTM’ in India, the company said.
Hetero launches FDC combination of key HIV drugsThe FDC drug ‘Darunavir+Ritonavir’ is an anti-retroviral medication indicated for the treatment of human immunodeficiency virus (HIV-1) in ...
Hetero gets DCGI nod for generic chronic hepatitis C drugThe company "has received the approval for the generic version of 'Sofosbuvir+Velpatasvir' combination from the Drugs Controller General of...
Hetero launches biosimilar Rituximab in IndiaHetero has launched biosimilar Rituximab in India used for treatment of certain types of cancers and rheumatoid arthritis under the brand n...
Swine flu: Hetero Healthcare increases Fluvir production by 400%Hetero has dedicated manufacturing facilities at Visakhapatnam in Andhra Pradesh and Baddi in Himachal Pradesh exclusively to produce the d...
Apollo Hospitals Enterprise to acquire HMSL's pharmacy stores for about Rs 146 croreApollo Hospitals Enterprise expects to leverage on it's proven track record of performance and operational capabilities to drive growth and...
- Hetero Labs to produce Gilead's HIV drugs, through Medicines Patent Pool
Hyderabad based Hetero labs through an agreement with Geneva based Medicines Patent Pool will produce four key HIV drugs developed by Gilea...
- Small firms all set to pep up pharma retail
Organised pharma retail, dominated by the likes of Apollo and Subiksha, is set for more action at the regional level.